» Articles » PMID: 27398141

Identification a Novel Tumor-suppressive Hsa-miR-599 Regulates Cells Proliferation, Migration and Invasion by Targeting Oncogenic MYC in Hepatocellular Carcinoma

Overview
Journal Am J Transl Res
Specialty General Medicine
Date 2016 Jul 12
PMID 27398141
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing evidences have demonstrated that microRNAs (miRNAs) act an essential role in regulating tumor progression and metastasis. Previous miRNAs microarray data showed that hsa-miR-599 is lower expressed in hepatocellular carcinoma (HCC); however, the function and molecular mechanism of hsa-miR-599 on HCC has not been well illustrated. Here, we first analyzed the expression level of hsa-miR-599 in HCC tissues and cell lines by real-time reverse-transcription PCR (qRT-PCR). Interestingly, we found that hsa-miR-599 was significantly down-regulated in the examined HCC tissues and cell lines. Then cells proliferation, migration and invasion were assessed by MTT, wound-healing and trans-well assay respectively. The results showed that over-expression of hsa-miR-599 resulted in inhibited HCC cells proliferation, migration and invasion in vitro. In addition, dual-luciferase reporter assay, qRT-PCR and Western blot analyzes were used to confirm MYC (v-myc avian myelocytomatosis viral oncogene homolog) as a target gene of hsa-miR-599. MYC expression was up-regulated in HCC tissues and cell lines, and restoration of hsa-miR-599 could remarkably decreased the mRNA and protein levels of MYC. Moreover, over-expression of MYC partly reversed hsa-miR-599-mediated inhibition of HCC cells proliferation, migration and invasion in vitro. Taken together, our data demonstrate that hsa-miR-599 acts as a tumor suppressor and inhibits HCC cells proliferation, migration and invasion by partly targeting oncogenic MYC, which hints that hsa-miR-599 can be a diagnostic and therapeutic biomarker in HCC.

Citing Articles

The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes.

Farsi N, Naghipour B, Shahabi P, Safaralizadeh R, Hajiasgharzadeh K, Dastmalchi N Clin Exp Hepatol. 2024; 9(4):307-319.

PMID: 38774201 PMC: 11103798. DOI: 10.5114/ceh.2023.131669.


The Role of Non-Coding RNAs in the Regulation of the Proto-Oncogene MYC in Different Types of Cancer.

Stasevich E, Murashko M, Zinevich L, Demin D, Schwartz A Biomedicines. 2021; 9(8).

PMID: 34440124 PMC: 8389562. DOI: 10.3390/biomedicines9080921.


Identification of a circRNA-miRNA-mRNA regulatory network for exploring novel therapeutic options for glioma.

He Y, Chen Y, Tong Y, Long W, Liu Q PeerJ. 2021; 9:e11894.

PMID: 34434651 PMC: 8351580. DOI: 10.7717/peerj.11894.


A microRNA Signature Identifies Patients at Risk of Barrett Esophagus Progression to Dysplasia and Cancer.

Saller J, Jiang K, Xiong Y, Yoder S, Neill K, Pimiento J Dig Dis Sci. 2021; 67(2):516-523.

PMID: 33713247 PMC: 9768694. DOI: 10.1007/s10620-021-06863-0.


MiR-599 Protects Cardiomyocytes against Oxidative Stress-Induced Pyroptosis.

Fan X, Zhan E, Yao Y, Zhang R, Sun Y, Tian X Biomed Res Int. 2021; 2021:3287053.

PMID: 33681353 PMC: 7906806. DOI: 10.1155/2021/3287053.


References
1.
Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

2.
Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer E, Saxena A . Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis. 2013; 34(12):2823-32. PMC: 3845895. DOI: 10.1093/carcin/bgt307. View

3.
Huang X, Jia Z . Construction of HCC-targeting artificial miRNAs using natural miRNA precursors. Exp Ther Med. 2013; 6(1):209-215. PMC: 3735510. DOI: 10.3892/etm.2013.1111. View

4.
Boyault S, Rickman D, De Reynies A, Balabaud C, Rebouissou S, Jeannot E . Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2006; 45(1):42-52. DOI: 10.1002/hep.21467. View

5.
Zhu L, Liu R, Zhang W, Qian S, Wang J . MicroRNA-205 regulates ubiquitin specific peptidase 7 protein expression in hepatocellular carcinoma cells. Mol Med Rep. 2015; 12(3):4652-4656. DOI: 10.3892/mmr.2015.3998. View